-
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
Cancer Res. 1993 Aug 1;53(15):3603-10
PMID: 8339266
-
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science. 2004 Jul 16;305(5682):399-401
PMID: 15256671
-
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Blood. 2005 Feb 15;105(4):1717-23
PMID: 15486067
-
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Cancer Res. 2002 Nov 1;62(21):5995-8
PMID: 12414617
-
Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis.
Cell Death Differ. 2004 Mar;11(3):290-300
PMID: 14657961
-
Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
Oncogene. 2006 Jul 27;25(32):4483-90
PMID: 16547503
-
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
J Clin Invest. 1993 Oct;92(4):1925-39
PMID: 8408645
-
Caspase-dependent cleavage of c-Abl contributes to apoptosis.
Mol Cell Biol. 2003 Apr;23(8):2790-9
PMID: 12665579
-
High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate.
Anal Biochem. 2001 Apr 15;291(2):279-89
PMID: 11401302
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med. 2001 Apr 5;344(14):1031-7
PMID: 11287972
-
Effects of antioxidants and caspase-3 inhibitor on the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human PLC/PRF/5 cells.
Eur J Pharmacol. 2005 Aug 22;518(2-3):96-106
PMID: 16054126
-
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.
Blood. 2001 Jun 1;97(11):3491-7
PMID: 11369642
-
Janus kinase 2: a critical target in chronic myelogenous leukemia.
Cancer Res. 2006 Jul 1;66(13):6468-72
PMID: 16818614
-
Flying under the radar: the new wave of BCR-ABL inhibitors.
Nat Rev Drug Discov. 2007 Oct;6(10):834-48
PMID: 17853901
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 2001 Aug 3;293(5531):876-80
PMID: 11423618
-
Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Nat Rev Cancer. 2007 Jun;7(6):441-53
PMID: 17522713
-
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood. 2007 Apr 15;109(8):3207-13
PMID: 17185463
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer Cell. 2002 Aug;2(2):117-25
PMID: 12204532
-
The biology of chronic myeloid leukemia.
N Engl J Med. 1999 Jul 15;341(3):164-72
PMID: 10403855
-
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.
Mol Pharmacol. 2002 Jan;61(1):222-9
PMID: 11752224
-
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
N Engl J Med. 2002 Feb 28;346(9):645-52
PMID: 11870241
-
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Nat Rev Cancer. 2005 Mar;5(3):172-83
PMID: 15719031
-
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Leukemia. 2005 Dec;19(12):2153-8
PMID: 16193082
-
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood. 2003 Jul 1;102(1):276-83
PMID: 12623848
-
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.
Blood. 2006 Jul 1;108(1):319-27
PMID: 16527898
-
Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents.
Biochem Pharmacol. 2004 Aug 15;68(4):659-66
PMID: 15276073
-
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Cancer Res. 2007 Feb 15;67(4):1680-8
PMID: 17308109
-
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
Blood. 2006 Oct 1;108(7):2332-8
PMID: 16772610
-
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.
Blood. 2003 May 15;101(10):4098-104
PMID: 12531810
-
Circumventing resistance to kinase-inhibitor therapy.
N Engl J Med. 2006 Jun 15;354(24):2594-6
PMID: 16775240
-
p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases.
Br J Haematol. 2002 Jun;117(3):588-97
PMID: 12028026
-
N-acetyl-cysteine enhances growth in BCR-ABL-transformed cells.
Cancer Sci. 2005 Apr;96(4):240-4
PMID: 15819723
-
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
J Biol Chem. 2000 Aug 11;275(32):24273-8
PMID: 10833515
-
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Biochem Biophys Res Commun. 2004 Jul 9;319(4):1272-5
PMID: 15194504
-
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.
Cancer Cell. 2006 Sep;10(3):241-52
PMID: 16959615
-
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Haematologica. 2007 Jun;92(6):838-41
PMID: 17550858
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N Engl J Med. 2006 Jun 15;354(24):2531-41
PMID: 16775234